Skip to main content

EVPRP Staff Bio

Thomas R. Verhoeven, Ph.D.

Thomas R. Verhoeven, Ph.D. President’s Fellow for Pharmaceuticals Development and Partnerships
Phone: (765) 496-1019

Thomas (Tom) Verhoeven joined Purdue as the President’s Fellow for Pharmaceuticals Development and Partnerships in July 2016. This position provides Purdue faculty and staff with a seasoned advocate to guide the development and commercialization opportunities of drug discovery. He is directly involved in building alliances among research collaborators and industry partners to increase the impact of drug discovery at Purdue University.

Verhoeven received a Bachelor of Science degree in chemistry from the University of Michigan. He completed his doctorate in organic chemistry at the University of Wisconsin and then accepted an appointment as a National Institutes of Health (NIH) fellow at Stanford University.

Verhoeven’s early research interests spanned multiple disciplines, including the use of polyanion intermediates in synthesis, enantioselective reduction methods, bioconversion applications, catalysis and reaction engineering. He has published and lectured widely on these topics and holds over 40 patents across a range of technologies. It was during these early research years that he became convinced of the untapped, innovative potential of interdisciplinary research. Fostering R&D collaboration across functional borders would become the cornerstone guiding his leadership approach throughout his professional career.

Upon completing his research appointment at Stanford, Verhoeven accepted a position within the Merck Research Laboratories, a division of Merck and Company. He began his career at Merck as a laboratory scientist. During his 23 year tenure at Merck, he accepted multiple assignments that broadened his experience and responsibilities in all phases of R&D. His consistent leadership focus in each role was on better integrating the multiple disciplines required to bring medicines from the lab to the patient. In this regard, he contributed to the development and commercialization of multiple products. These therapies included Mevacor, Zocor, Crixivan, Rizatriptan, Cozaar, Singulair and Cancidas. He also served as the Senior Vice President of Global Operations and Strategic Research Planning during a period of significant R&D expansion and consolidation at Merck.

Purdue University, West Lafayette, IN 47907 (765) 494-4600

© 2021 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by Office of the Executive Vice President for Research and Partnerships

If you have trouble accessing this page because of a disability, please contact Office of the Executive Vice President for Research and Partnerships at